Fennec Pharmaceuticals Inc. [FENCF]

Source: 

Company Overview

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on our only product candidate PEDMARK  . On September 20, 2022, we received approval from the FDA for PEDMARK to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.